Novartis announces results from five-year analysis of NATALEE trial of Kisqali

Novartis (NVS) announced results from the five-year analysis of the pivotal Phase 3 NATALEE trial of Kisqali that demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali. Results showed a 28.4% reduction in risk of recurrence in the broadest population of patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer treated with Kisqali plus endocrine therapy compared to ET alone. The five-year invasive disease-free survival rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement. These late-breaking results will be presented at the European Society for Medical Oncology Congress 2025, the company noted.